U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C19H14N2O2S
Molecular Weight 334.392
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TIDEGLUSIB

SMILES

O=C1SN(C(=O)N1CC2=CC=CC=C2)C3=CC=CC4=C3C=CC=C4

InChI

InChIKey=PMJIHLSCWIDGMD-UHFFFAOYSA-N
InChI=1S/C19H14N2O2S/c22-18-20(13-14-7-2-1-3-8-14)19(23)24-21(18)17-12-6-10-15-9-4-5-11-16(15)17/h1-12H,13H2

HIDE SMILES / InChI

Molecular Formula C19H14N2O2S
Molecular Weight 334.392
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Tideglusib (NP031112, NP-12, Nypta, Noscira SA, Madrid, Spain), a drug, which belongs to the thiadiazolidinone family, is a GSK-3β inhibitor. Tideglusib was in phase II clinical trials for the treatment of Alzheimer disease (AD) and progressive supranuclear palsy. Participants showed no benefit on either of the primary outcome measures or exploratory endpoints and further development in the drug was halted for these two disease. However, Tideglusib is on phase II clinical trial to determine whether drug is safe and efficacious in the treatment of adolescents and adults with congenital and juvenile-onset Myotonic Dystrophy.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P49841
Gene ID: 2932.0
Gene Symbol: GSK3B
Target Organism: Homo sapiens (Human)
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.
2011
Exploring the binding sites of glycogen synthase kinase 3. Identification and characterization of allosteric modulation cavities.
2011 Dec 22
Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds.
2011 Jun 23
Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.
2012 Jan 6
Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study.
2013
Patents

Patents

Sample Use Guides

1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
Route of Administration: Oral
Tideglusib is an irreversible inhibitor of GSK-3β. The interaction of tideglusib with GSK-3β, binding studies with radioactive compound were performed. [35S]tideglusib (207 Bq/nmol) at 55 μM was incubated with 5 μM GSK-3β for 1 h at 25 °C in 315 μl of 50 mM Tris-HCl, pH 7.5, containing 150 mM NaCl and 0.1 mM EGTA.
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:25:10 GMT 2023
Edited
by admin
on Fri Dec 15 17:25:10 GMT 2023
Record UNII
Q747Y6TT42
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TIDEGLUSIB
INN   WHO-DD  
INN  
Official Name English
4-BENZYL-2-(A-NAPHTHYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE
Common Name English
NP-031112
Code English
NP-12
Code English
4-BENZYL-2-(A-NAPHTYL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE
Common Name English
4-BENZYL-2-(NAPHTHALEN-1-YL)-1,2,4-THIADIAZOLIDINE-3,5-DIONE
Systematic Name English
tideglusib [INN]
Common Name English
NP031112
Code English
Tideglusib [WHO-DD]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/15/1452
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
FDA ORPHAN DRUG 290109
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
FDA ORPHAN DRUG 577417
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
NCI_THESAURUS C471
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
Code System Code Type Description
PUBCHEM
11313622
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
DRUG BANK
DB12129
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
EPA CompTox
DTXSID90235682
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
SMS_ID
100000177254
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
NCI_THESAURUS
C97364
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545157
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
INN
9223
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
FDA UNII
Q747Y6TT42
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
CAS
865854-05-3
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
WIKIPEDIA
Tideglusib
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
CHEBI
147398
Created by admin on Fri Dec 15 17:25:10 GMT 2023 , Edited by admin on Fri Dec 15 17:25:10 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
IRREVERSIBLE INHIBITOR
Related Record Type Details
ACTIVE MOIETY